Dosage and administration of Anti-c5 antibodies for treating delayed graft function (DGF)

TW202641844APending Publication Date: 2026-10-16ALEXION PHARMACEUTICALS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
TW115102565
Authority / Receiving Office
TW · TW
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-01-23
Filing Date
2026-01-22
Publication Date
2026-10-16

Smart Images

  • Figure TWG2TA001081009_001
    Figure TWG2TA001081009_001
  • Figure TWG2TA001081009_002
    Figure TWG2TA001081009_002
  • Figure TWG2TA001081009_003
    Figure TWG2TA001081009_003
Patent Text Reader

Abstract

Provided herein are dosages and methods for treating a human kidney transplant recipient, as well as methods for reducing the severity of delayed graft function (DGF) in a human kidney transplant recipient, by administering to the recipient an anti‑C5 antibody, or antigen binding fragment thereof (e.g., such as ravulizumab (ULTOMIRIS) prior to transplantation.
Need to check novelty before this filing date? Find Prior Art